Lifeboat Foundation

Noradrenaline-targeting drugs, including blood pressure, depression, and ADHD meds, improve Alzheimer’s disease symptoms.

From wearable electronics to microscopic sensors to telemedicine, new advances like graphene and supercapacitors are already here.

Americans endlessly chatter about what to eat. Low fat, high protein, vegan, ketogenic — but what about electronic? Since the turn of the 21st century, a dedicated group of scientists, engineers, and technologists has been trying to create edible electronics, not necessarily for human nutrition, but rather for medical purposes.

Electronic devices composed of digestible materials that gradually break down in the body over a matter of days could precisely deliver medication inside the body and measure drug uptake. They could monitor symptoms of gastrointestinal disorders and the gut microbiome. They could allow doctors to remotely observe patients’ internal health without a visit to the hospital, further enhancing the telehealth revolution and allowing more people access to healthcare.

Several proteins have been identified in hosts that interact with Ebola virus and primarily function to inhibit the production of viral genetic material in cells and prevent Ebola virus infection, according to a study led by the Institute for Biomedical Sciences at Georgia State University.

Zaire ebolavirus or Ebola virus, an RNA virus pathogen that belongs to the filovirus family, causes outbreaks of severe disease in humans. This public health threat has produced outbreaks where reported case fatality rates ranged up to 90 percent.

The West Africa Ebola virus epidemic from 2013–2016 resulted in more than 28,000 infections and more than 11,000 deaths. Four outbreaks occurred in the Democratic Republic of Congo from 2017–2021 and Ebola virus reemerged in Guinea in 2021.

Coronaviruses have brought about three massive outbreaks in the past two decades. Each step of its life cycle invariably depends on the interactions among virus and host molecules. The interaction between virus RNA and host protein (IVRHP) is unique compared to other virus-host molecular interactions, and has emerged to be a very hot topic in recent studies.

These studies provide essential information for a deeper understanding of IVRHP, which represents not only an attempt by viruses to promote their translation/replication, but also the host’s endeavor to combat viral pathogenicity. In other words, there is an urgent need to have a panorama of coronavirus RNA-Host protein interactions, which will then aid in the discovery of new antiviral therapies.

On October 6, 2022, Prof. Zhu Feng from College of Pharmaceutical Sciences in Zhejiang University, Prof. Han Lianyi from College of Life Sciences in Fudan University and Prof. Lin Tao from College of Pharmaceutical Sciences in Hangzhou Normal University published an article titled “CovInter: Interaction Data between Coronavirus RNAs and Host Proteins” in Nucleic Acids Research.

A team of scientists at Whitehead Institute and the Broad Institute of MIT and Harvard have systematically evaluated the functions of more than 5,000 essential human genes using a novel, pooled, imaged-based screening method. Their analysis harnesses CRISPR/Cas9 to knock out gene activity and forms a first-of-its-kind resource for understanding and visualizing gene function in a wide range of cellular processes with both spatial and temporal resolution.

The team’s findings, published in the journal Cell, span over 31 million individual cells and include quantitative data on hundreds of different parameters that enable predictions about how genes work and operate together.

“For my entire career, I’ve wanted to see what happens in cells when the function of an essential gene is eliminated,” said Iain Cheeseman, a senior author of the study and a member of Whitehead Institute. “Now, we can do that, not just for one gene but for every single gene that matters for a human cell dividing in a dish, and it’s enormously powerful. The resource we’ve created will benefit not just our own lab but labs around the world.”

Using an approach based on CRISPR proteins, MIT researchers have developed a new way to precisely control the amount of a particular protein that is produced in mammalian cells.

This technique could be used to finely tune the production of useful proteins, such as the monoclonal antibodies used to treat cancer and other diseases, or other aspects of cellular behavior. In their new study, which appears in Nature Communications, the researchers showed that this system can work in a variety of mammalian cells, with very consistent results.

“It’s a highly predictable system that we can design up front and then get the expected outcome,” says William C.W. Chen, a former MIT research scientist. “It’s a very tunable system and suitable for many different biomedical applications in different cell types.”

A team of researchers at Umeå University has discovered that an enzyme in human cells has probably evolved from an ancient single-celled organism. The enzyme’s unique properties mean that it could be used as a building block in the design of new enzymes, for example in processing wood raw materials. The discoveries are presented in Science Advances.

Life on Earth is divided into three groups of organisms: bacteria, archaea and eukaryotes, with humans belonging to the last group, the eukaryotes. One theory is that we evolved from archaea, which in turn may have evolved from bacteria.

Now, a team of researchers from the Department of Chemistry at Umeå University has discovered clear traces of an archaea (odinarchaeota) in an enzyme found in the nucleus of human cells. The human enzyme is called AK6 and has a variety of functions, such as energy metabolism, genome stabilization and programmed cell death.

The human genome has just over 20,000 genes coding for proteins. Yet, it produces at least ten times that many different non-coding RNA molecules, which can often take on more than one shape. At least some of this RNA structurome is functional in physiology or pathophysiology.

In an invited review for Nature Reviews Genetics, Danny Incarnato, a molecular geneticist from the University of Groningen (The Netherlands), and his colleague Robert C. Spitale from the University of Irvine in California (USA) describe ways to develop the, as yet, largely untapped potential of RNA structures.

RNA is perhaps best known as the intermediate between genome and protein synthesis: messenger RNA molecules copy the genetic code of a gene in the cell’s nucleus and transport it to the cytoplasm, where ribosomes translate the code into a protein. However, RNA is also a key regulator of almost every cellular process and the structures that are adopted by RNA molecules are thought to often be key to their functions.